Canaccord lowered the firm’s price target on Boston Scientific to $60 from $64 and keeps a Buy rating on the shares. The firm said they repeorted a strong Q3 beat and they believe the company is set up for continued strong organic growth with a strong cadence of expected US product launches coming late next year, including Farapulse (PFA), Acurate neo2 (TAVR), and Agent (DCB).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BSX:
- BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER 2023
- Boston Scientific raises FY23 adjusted EPS view to $1.99-$2.02 from $1.96-$2.00
- Boston Scientific sees Q4 adjusted EPS 49c-52c, consensus 52c
- Boston Scientific reports Q3 adjusted EPS 50c, consensus 48c
- Boston Scientific reports ‘positive’ 12-month results from AGENT IDE trial